Skip to main content

Table 2 Doses of tolvaptan administered

From: Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease

Protein uria

< 0.15 g/gCr

0.15-0.49 g/gCr

> 0.50 g/gCr

CKD stage

    

GFR (mL/min/1.73m2)

90

120 (case 1)

  

60~ 89

   

45~ 59

90/90 (case 2 and 3)

  

30~ 44

120/90 (case 4 and 5)

  

15~ 29

 

90 (case 6)

 

< 15

   
    

(mg/day)

  1. Cases 1 and 4 were treated with 120 mg/day tolvaptan. Cases 2, 3, 5, and 6 were treated with 90 mg/day tolvaptan